WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.

PRNewsWire • 9 hours ago

Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today

Vertex Pharmaceuticals (VRTX) reached $470.1 at the closing of the latest trading day, reflecting a -1.17% change compared to its last close.

Zacks Investment Research • Jan 30, 2026

Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals

Vertex Pharmaceuticals could have several important catalysts this year. The stock's long-term outlook seems highly attractive.

The Motley Fool • Jan 29, 2026

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

Seeking Alpha • Jan 27, 2026

Wall Street Analysts Think Vertex (VRTX) Is a Good Investment: Is It?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • Jan 23, 2026

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $467.35, signifying a +1.35% move from its prior day's close.

Zacks Investment Research • Jan 23, 2026

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television • Jan 22, 2026

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call.” The conference call will be webcast live and a lin.

Business Wire • Jan 20, 2026

My Forever Portfolio: 5 Stocks I Don't Plan on Ever Selling

This "forever" portfolio includes two "Magnificent Seven" stocks that should remain magnificent. It features a conglomerate that's preserving its long-time leader's legacy.

The Motley Fool • Jan 19, 2026

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $438.92, representing a -2.36% change from its previous close.

Zacks Investment Research • Jan 16, 2026